Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.8M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$131M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Zanganeh Mahkam | Mar 27, 2024 | Buy | 34,321 | $3.72 | $130,000 |
| Zanganeh Mahkam | Mar 27, 2024 | Buy | 26,000 | $3.72 | $97,000 |
| Zanganeh Mahkam | Mar 27, 2024 | Buy | 20,000 | $3.71 | $74,000 |
| Dhingra Ankur | Mar 26, 2024 | Buy | 100,000 | $3.75 | $380,000 |
| Zanganeh Mahkam | Mar 26, 2024 | Buy | 30,000 | $3.75 | $110,000 |
| Dhingra Ankur | Dec 13, 2023 | Buy | 19,700 | $2.17 | $43,000 |
| Dhingra Ankur | Dec 13, 2023 | Buy | 700 | $2.15 | $1,500 |
| Zanganeh Mahkam | Dec 12, 2023 | Buy | 5,000 | $2.07 | $10,000 |
| Soni Manmeet Singh | Oct 13, 2023 | Buy | 2,976,190 | $1.68 | $5M |
| Zanganeh Mahkam | Mar 8, 2023 | Buy | 15,973,743 | $1.05 | $17M |
| Zanganeh Mahkam | Mar 8, 2023 | Buy | 16,778,415 | $1.05 | $18M |
| Zanganeh Mahkam | Mar 8, 2023 | Buy | 6,748,629 | $1.05 | $7.1M |
| Zanganeh Mahkam | Mar 8, 2023 | Buy | 6,748,629 | $1.05 | $7.1M |
| Zanganeh Mahkam | Mar 8, 2023 | Buy | 804,672 | $1.05 | $840,000 |
| Xia Yu | Mar 7, 2023 | Buy | 21,523,530 | $1.05 | $23M |
| Dhingra Ankur | Mar 7, 2023 | Buy | 196,362 | $1.05 | $210,000 |
| DUGGAN ROBERT W | Mar 6, 2023 | Buy | 376,489,880 | $1.05 | $395M |
| Xia Yu | Jan 17, 2023 | Buy | 10,000,000 | $2.51 | $25M |
What's the latest insider transaction for Summit Therapeutics?
The most recent insider transaction for Summit Therapeutics was conducted by Zanganeh Mahkam, who sold 34,321 shares on March 27, 2024 at a price of $3.72 per share.
Which insider bought the most SMMT stock over the last two years?
DUGGAN ROBERT W has bought the most SMMT stock in the last 2 years, with a total value of $395M.
What is the total value of insider transactions for Summit Therapeutics (SMMT) in the last 2 years?
According to our estimates, the total value of insider transactions for Summit Therapeutics in the last 2 years is positive, amounting to $498M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
How do insider transactions over the last 2 years reflect on Summit Therapeutics' market confidence?
Over the last 2 years, insider transactions for Summit Therapeutics have predominantly involved purchasing shares, indicating a strong confidence among insiders in the company's future prospects. This trend of more purchases than sales could be a positive signal to potential investors about the insiders' view on the company's valuation and growth potential.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
